Betty Fan1, Jaime A Pardo1, Stephanie Serres1, Amulya C Alapati1, Joanne Szewczyk1, Alessandra Mele1, Ted A James2. 1. Department of Surgery, Breast Care Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 2. Department of Surgery, Breast Care Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ted.james@bidmc.harvard.edu.
Abstract
BACKGROUND: Microinvasive ductal carcinoma (DCISM), defined as DCIS with a focus of invasive carcinoma ≤ 1 mm, can be managed similarly to pure DCIS; however, management of the axilla in DCISM has been a subject of debate. Reports in the literature differ on the utility and necessity of sentinel lymph node biopsy (SLNB) for DCISM. The aim of the present study was to identify risk factors for nodal disease in patients with DCISM, which can help develop a selective approach to SLNB in this patient population. METHODS: The National Cancer Database was used to select patients with DCISM (pT1mi), diagnosed from 2012 to 2015, who underwent SLNB. Multivariable regression analysis was performed to determine associations between sentinel lymph node metastasis and relevant clinical variables. RESULTS: Our cohort comprised of 2609 patients with pT1mi who underwent SLNB. Of these, 76 (2.9%) were found to have sentinel lymph node metastases on final pathology. Low/intermediate grade tumors were associated with decreased SLN metastasis (OR 0.50, CI 0.28-0.92). Age and receptor status of the tumor did not have a clear association in predicting SLN metastases. CONCLUSIONS: The rate of sentinel node metastases in DCISM is low at only 2.9% in this national study. Tumor grade was identified as influencing the risk of SLN metastases. This information can factor into shared decision-making for SLNB in patients with DCISM.
BACKGROUND:Microinvasive ductal carcinoma (DCISM), defined as DCIS with a focus of invasive carcinoma ≤ 1 mm, can be managed similarly to pure DCIS; however, management of the axilla in DCISM has been a subject of debate. Reports in the literature differ on the utility and necessity of sentinel lymph node biopsy (SLNB) for DCISM. The aim of the present study was to identify risk factors for nodal disease in patients with DCISM, which can help develop a selective approach to SLNB in this patient population. METHODS: The National Cancer Database was used to select patients with DCISM (pT1mi), diagnosed from 2012 to 2015, who underwent SLNB. Multivariable regression analysis was performed to determine associations between sentinel lymph node metastasis and relevant clinical variables. RESULTS: Our cohort comprised of 2609 patients with pT1mi who underwent SLNB. Of these, 76 (2.9%) were found to have sentinel lymph node metastases on final pathology. Low/intermediate grade tumors were associated with decreased SLN metastasis (OR 0.50, CI 0.28-0.92). Age and receptor status of the tumor did not have a clear association in predicting SLN metastases. CONCLUSIONS: The rate of sentinel node metastases in DCISM is low at only 2.9% in this national study. Tumor grade was identified as influencing the risk of SLN metastases. This information can factor into shared decision-making for SLNB in patients with DCISM.
Authors: April Phantana-Angkool; Amy E Voci; Yancey E Warren; Chad A Livasy; Lakesha M Beasley; Myra M Robinson; Lejla Hadzikadic-Gusic; Terry Sarantou; Meghan R Forster; Deba Sarma; Richard L White Journal: Ann Surg Oncol Date: 2019-07-24 Impact factor: 5.344
Authors: F Magnoni; G Massari; G Santomauro; V Bagnardi; E Pagan; G Peruzzotti; V Galimberti; P Veronesi; V S Sacchini Journal: Br J Surg Date: 2019-02-21 Impact factor: 6.939
Authors: Emil Villiam Holm-Rasmussen; Maj-Britt Jensen; Eva Balslev; Niels Kroman; Tove Filtenborg Tvedskov Journal: Breast Cancer Res Treat Date: 2019-03-14 Impact factor: 4.872
Authors: Pill Sun Paik; Nam Sun Paik; Eun Sook Lee; Jung Eun Choi; Joon Jeong; Hyun Jo Youn; Chang Ik Yoon; Soo Youn Bae; Tae-Kyung Yoo Journal: Ann Surg Treat Res Date: 2022-06-07 Impact factor: 1.766